Cost

Cost per project estimate: €5500

-immunisation up to 3 proteins

- screening method developed for specificity

- Nanobody repertoire amplified by RT-PCR

- cloned into phage display libraries

- Nanobodies selected

Possible Output

TBA

Description of service

Nanobodies are compact single Ig domains that bind target proteins with high affinity while reducing their coinformational heterogeneity, thereby stabilising multi-protein complexes. Their properties mean that nanobodies are versatile tools for structural biology.

 

Scientific relevance: Nanobody production has several applications relevant to vaccine design:

  • Nanobody/protein complexes may be more stable than individual proteins, favouring crystallisation

    for X-ray analysis (including intrinsically disordered proteins)

  • The CDR3 loop of nanobodies can extend into small cavities on antigenic surfaces which otherwise are

    difficult to measure or modulate, and nanobodies do not compete with classical antibodies that bind

    the same antigen. Some are in development as therapeutic agents.

  • Nanobody reagents can capture transient protein conformations

  • Nanobodies can be immuno-labelled for super-resolution imaging, spin-labelled for EPR spectroscopy

    or heavy metal labelled.

  • Small size can be used in NMR methods, can act as NMR invisible probes for dynamic studies of protein

    conformation.

Timeline 

2-4 months*

(longer if re-immunisation is required)

Contact 

Els Pardon, 

+ 32 2 629 19 95 

Els.Pardon@vub.be 

 

Jan Steyaert,

+ 32 2 629 19 31

jan.steyaert@vub.be

Lead Scientist

TBA

Publications

Example publications of nanobody use for structural analysis:

 

  • J Struct Biol. 2011 Apr; 174(1): 124–136. doi: 10.1016/j.jsb.2010.10.007 ‘STRUCTURES OF A KEY INTERACTION PROTEIN FROM THE TRYPANOSOMA BRUCEI EDITOSOME IN COMPLEX WITH SINGLE DOMAIN ANTIBODIES.’ Meiting Wu, Young-jun Park, Els Pardon, Stewart Turley, Andrew Hayhurst, Junpeng Deng, Jan Steyaert, and Wim G. J. Hol.

  • Vaccines (Basel). 2019 Sep; 7(3): 77. doi: 10.3390/vaccines7030077 ‘Nanobodies that Neutralize HIV.’ Robin A. Weiss and C. Theo Verrips.

Sample Requirements - input of users

2mg purified protein for immunisation (or cells expressing protein, or genetic vaccination)

Good assay for selecting nanobodies with appropriate properties

Nanobody production

Free 

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N° 730964.

Be the first to know about the upcoming application calls, follow European Vaccine Initiative on:

  • LinkedIn Social Icon
  • Twitter Social Icon
Subscribe to TRANSVAC´s Mailing list

© 2020 European Vaccine Initiative. Designed by European Vaccine Initiative